

We are an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment.

We enable healthier lives, everywhere, every day

As the leader in women's health, we deliver life-changing and life-saving diagnostic, detection, and surgical products that are rooted in science, driven by technology, and inspired by our desire to empower women and help healthcare professionals diagnose and treat their patients with growing certainty, precision, and ever-greater peace of mind.

Genius™ 3D™ exam

The Genius™ 3D Mammography™ exam¹ detects 20-65% more breast cancers compared to 2D mammography alone.²



Brevera® Breast Biopsy System

The Brevera® breast biopsy system with CorLumina® imaging technology is the world's first and only solution to combine tissue acquisition, real-time imaging, verification and advanced post-biopsy handling—all in one, integrated system.



Affirm® Prone Biopsy System

Superior biopsy imaging using Genius 3D technology. Improved workflow results in faster procedures and an enhanced patient experience.



Horizon™ DXA Bone Densitometry

Provides high-quality clinical images that reveal the smallest fractures at the earliest stage—helping to keep patients strong and healthy. Horizon™ was designed to assess osteoporosis, obesity and aortic calcifications.



NovaSure® for AUB

NovaSure endometrial ablation for abnormal uterine bleeding (AUB) can dramatically improve a woman's comfort, confidence and quality of life. It is a safe, simple solution used by more than 3 million women since 2001.



MyoSure® Hysteroscopic Tissue Removal

The MyoSure procedure enables fast, safe removal of fibroids, polyps and retained products of conception in less than 15 minutes—without having to make a single incision. It enables convenient removal of intrauterine pathology under direct visualization.



Panther® System

Offers best-in-class automation and workflow for molecular diagnostics, giving laboratories greater freedom and flexibility with true walk-away processing and random access sampling. Delivers a broad menu of the most sensitive, accurate, and precise assays.



Aptima® Molecular Diagnostic Assays

Hologic developed the first FDA-cleared nucleic acid test for infectious diseases over 30 years ago. Today, our state-of-the-art Aptima assays quickly identify diseases like chlamydia, gonorrhea, trichomoniasis, HIV-1, HCV and HBV at early stages, often within days of infection.



ThinPrep® Pap Test

Cervical cancer was the #1 cancer killer of women prior to the introduction of Pap screening, now it's #14.³ Hologic's ThinPrep liquid-based cytology test has revolutionized cervical cancer screening and is the leading cervical specimen collection product in the world.



SARS-CoV-2 Tests

To help fight COVID-19, Hologic developed the Panther Fusion® and Aptima SARS-CoV-2 assays, and scaled up to produce 1.5 million tests a week. The tests run on the world's largest installed base of more than 2,000 high-throughput instruments.



Fluoroscans® InSight™ Mini C-arm Extremities Imaging System

Provides excellent image quality and system versatility for all extremity imaging needs. The system is designed to help minimize radiation by preventing patient and surgeon exposure to the unused area of the detector.



©2020 Hologic, Inc. U.S./International. All rights reserved. Printed in the United States. Hologic, 3D Mammography, Affirm, Aptima, Brevera, Dimensions, Fluoroscans InSight, Genius, Horizon, MyoSure, NovaSure, Panther, Panther Fusion, Selenia, The Science of Sure and ThinPrep are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is not intended as a product solicitation or promotion. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear.

1. The Genius™ exam is only available on the Hologic® 3D Mammography™ system. Please visit <https://www.MyGenius3D.com> for more information. 2. Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25;311(24):2499-507. 3. <https://www.report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=76>

Financial Results

REVENUE HIGHLIGHTS 3Q20

NON-GAAP REVENUE (\$M)	3Q20	Reported Δ vs. 3Q19	CC Δ vs. 3Q19
Diagnostics ¹	\$532.2	74.3%	74.9%
Breast Health	\$224.0	(31.2%)	(30.9%)
GYN Surgical	\$51.5	(54.1%)	(53.9%)
Skeletal Health	\$15.2	(37.7%)	(37.3%)
Medical Aesthetics ⁵	\$-	N/A	N/A
Total Revenue	\$822.9	(3.5%)	(3.1%)
<i>Core Revenue³</i>	<i>\$815.1</i>	<i>8.2%</i>	<i>8.7%</i>
<i>Organic Revenue⁴</i>	<i>\$811.2</i>	<i>7.7%</i>	<i>8.1%</i>
US Organic	\$652.6	11.2%	11.2%
OUS Organic	\$158.6	(4.7%)	(2.8%)

FINANCIAL OVERVIEW 3Q20

NON-GAAP IN MILLIONS ex. EPS	3Q20	Δ vs. 3Q19
Revenue (\$M)	\$822.9	(3.5%)
<i>Core Revenue³</i>	<i>\$815.1</i>	<i>8.2%</i>
<i>Organic Revenue⁴</i>	<i>\$811.2</i>	<i>7.7%</i>
Gross Margin	64.7%	310 bps
Operating Expenses	\$261.1	(5.5%)
Operating Margin	33.0%	380 bps
Net Margin	23.7%	360 bps
Diluted EPS	\$0.75	19.0%
EBITDA	\$299.0	8.2%

FINANCIAL GUIDANCE FOR FOURTH QUARTER FISCAL 2020

NON-GAAP	4Q20	Reported vs. '19	CC vs. 4Q19	Organic % Increase
Revenue (\$M)	\$925 - \$1,025	6.8% to 18.4%	6.7% to 18.3%	17.4% to 30.3%
Diluted EPS	\$0.95 - \$1.15	46.2% to 76.9%		


CAPITAL DEPLOYMENT PRIORITIES

Business development:


- Tuck-in acquisitions
- Attractive to revenue, EPS growth rates
- Attractive ROIC
- Leveraging existing sales channels

Opportunistic share repurchases


NET DEBT & LEVERAGE RATIO²




REVENUE & CC GROWTH RATES




2019 DIVISIONAL REVENUE BY GEOGRAPHY




NON-GAAP EPS



% NET MARGIN



ROIC



1. Includes contributions from divested blood screening business. Excluding blood, Diagnostics sales increased 80.1% on a reported basis, or 80.8% in constant currency.

2. Net debt is total debt minus cash; leverage ratio is principal debt minus cash to TTM adjusted EBITDA.

3. Core Revenue excludes Blood Screening and Medical Aesthetics.

4. Organic Revenue excludes divested Blood Screening and Medical Aesthetics businesses, and acquired SSI business.

5. Divestiture of Medical Aesthetics business was completed on 12/30/19.